We originally posted on this last October (on our LinkedIn page, here) and now that the final numbers are in for 2019 we thought it would be good to revisit the topic.

‍

‍

With over 90 FDA warning letters issued throughout 2019, its critical to get quality control correct throughout the entire #pharma process, starting with #manufacturing and continuing along with the research, development and testing processes.

If the foundation isn’t solid to begin with, everything you build on top is useless. Do you agree?

Being successfully GMP, GLP, GCP certified and FDA audited multiple times, and with over 20-years experience of supporting the entire pharma cycle from start to finish, why not let QUINTA-ANALYTICA be your partner to success?

Get in touch with us today and let’s discuss your solution.

Additional News

  • 20 November 2025

    Webinar: Streamlined Evidence Strategies for Biosimilars: Analytics, PK and Immunogenicity in focus

    On behalf of Conscio Group, we are pleased to invite you to the upcoming free educational webinar from biosimilar series.

  • 11 September 2025

    Meet us at CPHI 2025

    This October, the global pharmaceutical community will gather in Frankfurt for CPHI 2025. Quinta-Analytica as a member of Conscio Group will be there too – visit us in the Contract Manufacturing Hall 5.1, Stand F1.

  • 8 September 2025

    Quinta-Analytica successfully passed two onsite FDA inspections

    In the first half of 2025, Quinta-Analytica underwent two onsite inspections by the U.S. Food and Drug Administration (FDA).

ALL POSTS